← Eichor
Study identifier: NCT06536400 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

Condition: Solid Tumors  ·  Sponsor: Haisco Pharmaceutical Group Co., Ltd.

PhasePhase 1
Planned participants316
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360 when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (13)

Peking University First HospitalBeijing, Beijing Municipality, ChinaRecruiting
Beijing TianTan Hospital,Capital Medical UniversityBeijing, Beijing Municipality, ChinaRecruiting
Beijing Cancer HospitalBeijing, Beijing Municipality, ChinaRecruiting
The First Affiliated Hospital of Fujian Medical UniversityFuzhou, Fujian, ChinaRecruiting
Sun Yat-Sen University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting
Guangxi Medical University Cancer HospitalNanning, Guangxi, ChinaRecruiting
The Third People's Hospital of ZhengzhouZhengzhou, Henan, ChinaRecruiting
Hunan Cancer HospitalChangsha, Hunan, ChinaRecruiting
Hunan Cancer HospitalChangsha, Hunan, ChinaRecruiting
Nanjing Drum Tower HospitalNanjing, Jiangsu, ChinaRecruiting
Nanjing Drum Tower HospitalNanjing, Jiangsu, ChinaRecruiting
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, ChinaRecruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06536400